References
- 1. Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2015;67-11910.1093/eurheartj/ehv317
- 2. Matthews DT, Hemnes AR. Current concepts in the pathogenesis of chronic thromboembolic pulmonary hypertension. Pulm Circ. 2016;6(2):145-5410.1086/686011
- 3. Wolf M, Boyer-Neumann C, Parent F, et al. Thrombotic risk factors in pulmonary hypertension. Eur Respir J 2000;15: 395–9.10.1034/j.1399-3003.2000.15b28.x
- 4. Bonderman D, Turecek PL, Jakowitsch J, et al. High prevalence of elevated clotting factor VIII in chronic thromboembolic pulmonary hypertension. Thromb Haemost 2003;90:372–610.1160/TH03-02-0067
- 5. Lang I, Kerr K. Risk Factors for Chronic Thromboembolic Pulmonary Hypertension. Proc Am Thorac Soc 2006;3(7):568–7010.1513/pats.200605-108LR
- 6. Pepke-Zabka J, Jansa P, Kim NH, et al. Chronic thromboembolic pulmonary hypertension: role of medical therapy. Eur Respir J 2013;41:985–9010.1183/09031936.00201612
- 7. Lang IM, Pesavento R, Bonderman D, Yuan JX. Risk factors and basic mechanisms of chronic thromboembolic pulmonary hypertension: a current understanding. Eur Respir J 2013;41(2):462–810.1183/09031936.00049312
- 8. Fedullo PF, Auger WR, Kerr KM, et al. Chronic thromboembolic pulmonary hypertension. N Engl J Med 2001;345(20):1465–7210.1056/NEJMra010902
- 9. Mayer E, Jenkins D, Lindner J, et al. Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. J Thorac Cardiovasc Surg, 2011;141(3):702-1010.1016/j.jtcvs.2010.11.024
- 10. Jamieson SW, Kapelanski DP, Sakakibara N, et al. Pulmonary endarterectomy: experience and lessons learned in 1,500 cases. Ann Thorac Surg 2003;76(5):1457–6210.1016/S0003-4975(03)00828-2
- 11. Ghofrani HA, D’Armini AM, Grimminger F, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med. 2013; 369(4): 319-2910.1056/NEJMoa1209657
- 12. Satoh T, Kataoka M, Inami T, et al. Endovascular treatment for chronic pulmonary hypertension: a focus on angioplasty for chronic thromboembolic pulmonary hypertension. Expert Rev Cardiovasc Ther. 2016;14(9):1089-9410.1080/14779072.2016.1208083
- 13. He J, Fang W, Lv B, et al. Diagnosis of chronic thromboembolic pulmonary hypertension: comparison of ventilation/perfusion scanning and multidetector computed tomography pulmonary angiography with pulmonary angiography. Nucl Med Commun 2012;33:459–6310.1097/MNM.0b013e32835085d9
- 14. Lang IM, Plank C, Sadushi-Kolici R, et al. Imaging in pulmonary hypertension. JACC Cardiovasc Imaging 2010;3:1287–9510.1016/j.jcmg.2010.09.013
- 15. Li Y, Zhu J, Ding JQ. VKORC1 rs2359612 and rs9923231 polymorphisms correlate with high risks of cardiovascular and cerebrovascular diseases. Genet Mol Res. 2015;14(4):14731-44.10.4238/2015.November.18.38
- 16. Wang J, Wang C, Chen N, et al. Association between the plasminogen activator inhibitor-1 4G/5G polymorphism and risk of venous thromboembolism: a meta-analysis. Thromb Res. 2014;134(6):1241-810.1016/j.thromres.2014.09.035
- 17. Heneghan C, Ward A, Perera R. Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. Lancet 2012; 379: 322–3410.1016/S0140-6736(11)61294-4